Cardio-metabolic disorders
We have a long history of making an impact in cardio-metabolic disorders, such as type 2 diabetes and cardiovascular disease.
Our focus on cardio-metabolic disorders research and treatments
We introduced our first cardiovascular therapy more than 60 years ago, and we continue our scientific efforts to deeply understand cardio-metabolic disorders. Cardio-metabolic disorders include cardiovascular diseases, such as heart failure and pulmonary arterial hypertension (PAH), and metabolic diseases, such as type 2 diabetes. They represent some of the most serious health challenges of the 21st century.
Advancements in cardio-metabolic research can make an impactful difference for patients, and there’s still much more work to be done. We strive for scientific excellence and innovation in all stages of research, from discovery through approval and afterwards.
The impact of cardio-metabolic disorders
Annual deaths worldwide from cardiovascular disease in 2020
Adults worldwide predicted to have diabetes by 2030
people in Switzerland live with PAH, and about 50 new cases are diagnosed annually
Cardiovascular disease
Cardiovascular disease remains one of the leading health challenges worldwide.
We continue to build on our history of innovative therapies in cardiovascular disease to help increase our understanding and help patients around the world.
We work with experts throughout the cardiovascular community to advance research that can help improve the lives of patients with cardiovascular risk.
Diabetes
Diabetes is one of the fastest growing health concerns of the 21st century, with the number of adults living with diabetes having more than tripled over the past 20 years.
We’re proud of our research team that is committed to helping people with type 2 diabetes.
Pulmonary arterial hypertension (PAH)
Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening blood vessel disorder in which the pulmonary arteries—the vessels that carry blood from the right side of the heart to the lungs—become thickened and narrowed. As a result, the heart has to work harder to pump blood into the lungs, placing increasing strain on the cardiovascular system.
We are committed to advancing research and developing solutions that can improve the lives of people affected by PAH.
Our online platforms for patients and healthcare professionals
Anyone diagnosed with a chronic disease desires information and has questions about how best to live with the disease. That’s why we offer patients extensive knowledge about their disease in easy-to-understand language and a variety of tips for everyday life. For healthcare professionals, we offer up-to-date scientific information and tools for daily practice in our web portal.
Online platform for patients
msd-gesundheit.ch is our online platform exclusively for patients. Here you will find the most important information explained in an easy-to-understand way. This includes information about the disease, symptoms and treatment options, as well as tips for everyday life.
Online platform for healthcare professionals
Are you a healthcare professional looking for scientific information?
Discover mymsd.ch, our web portal exclusively for healthcare professionals. It offers information on MSD medicines, study summaries as video and PDF, current publications on the safety and efficacy of MSD medicines, access to the online store for ordering MSD products, information material for physicians and patients, and much more.
CH-NON-02906, 03/2025
